Anoor Paripati, MBBS, Chris Kingsley, PhD, Glen J. Weiss, MD

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non– Small-Cell Lung Cancer Yen-Ting Lin, MD, Yu-Fen Wang, MD, James Chih-Hsin.

A Hole in the Heart Journal of Thoracic Oncology

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

SC17.02 Lung Cancer in China: Challenges and Perspectives

ALK FISH and IHC: You Cannot Have One without the Other

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

NA Journal of Thoracic Oncology

Electronic Updates for JTO Readers

Hedgehog Signaling Pathway and Lung Cancer

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Frank Detterbeck, MD Journal of Thoracic Oncology

The Thymus and the Immune System: Layered Levels of Control

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Vascular Endothelial Growth Factor (VEGF) Pathway

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis

Prevention and Management of Bone Metastases in Lung Cancer: A Review

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

A Hole in the Heart Journal of Thoracic Oncology

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors Sophie Feng, M.B.B.S., Jermaine Coward, PhD,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

Mitotic Inhibitors Journal of Thoracic Oncology

A Translational View of the Molecular Pathogenesis of Lung Cancer

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Benjamin Solomon, MBBS, PhD, Richard B. Pearson, PhD

Table of contents The Journal for Nurse Practitioners

Pulmonary Metastasectomy in Breast Cancer

MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next- Generation Sequencing and Successfully Treated with a MET Inhibitor Carrie.

Phase I Study of Lenalidomide in Solid Tumors

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

The Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Lung Cancer: Still Following the Right TRAIL? Emmet E. McGrath, MB, PhD Journal of Thoracic.

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Table of Contents Journal of Thoracic Oncology

Genetic Changes in Squamous Cell Lung Cancer: A Review

Table of contents The Journal for Nurse Practitioners

Ethnic Differences in the Management of Lung Cancer in New Zealand

European Lung Cancer Conference (ELCC) 2016 Organisation

Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,

S-1 Treatment for Chemorefractory Thymic Carcinoma

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Tumor Lysis Syndrome in Limited-Stage Small-Cell Lung Cancer

David Garfield, MD Journal of Thoracic Oncology

Samuel Kim, MD The Journal of Thoracic and Cardiovascular Surgery

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

A Review of First-Line Treatment for Small-cell Lung Cancer

Role of the Wnt Signaling Pathway and Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Presentation transcript:

Pathway Targets to Explore in the Treatment of Small Cell and Large Cell Lung Cancers Anoor Paripati, MBBS, Chris Kingsley, PhD, Glen J. Weiss, MD Journal of Thoracic Oncology Volume 4, Issue 11, Pages 1313-1321 (November 2009) DOI: 10.1097/JTO.0b013e3181ba20cf Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Amyotrophic Lateral Sclerosis Signaling pathway and potential targeting drugs This illustration details the interactions of targets with the potential targeting agents (ellipse with Rx followed by drug name) connected by solid line(s). Additional proteins and targets in this pathway (for which no current drug has been identified) are depicted. Types of interaction relationships are annotated in the figure. Additional drugs for targets are annotated in Supplementary Table 1 (Supplemental Digital Content 2, http://links.lww.com/JTO/A10). Data were analyzed through the use of Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com) and printed with permission. Journal of Thoracic Oncology 2009 4, 1313-1321DOI: (10.1097/JTO.0b013e3181ba20cf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Cell cycle: G2/M DNA Damage Checkpoint Regulation pathway and potential targeting drugs This illustration details the interactions of targets with the potential targeting agents (ellipse with Rx followed by drug name) connected by solid line(s). Additional proteins and targets in this pathway (for which no current drug has been identified) are depicted. Types of interaction relationships are annotated in the figure. Additional drugs for targets are annotated in Supplementary Table 2 (Supplemental Digital Content 2, http://links.lww.com/JTO/A10). Data were analyzed through the use of Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com) and printed with permission. Journal of Thoracic Oncology 2009 4, 1313-1321DOI: (10.1097/JTO.0b013e3181ba20cf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 p53 Signaling pathway and potential targeting drugs This illustration details the interactions of targets with the potential targeting agents (ellipse with Rx followed by drug name) connected by solid line(s). Additional proteins and targets in this pathway (for which no current drug has been identified) are depicted. Types of interaction relationships are annotated in the figure. Additional drugs for targets are annotated in Supplementary Table 5 (Supplemental Digital Content 2, http://links.lww.com/JTO/A10). Data were analyzed through the use of Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com) and printed with permission. Journal of Thoracic Oncology 2009 4, 1313-1321DOI: (10.1097/JTO.0b013e3181ba20cf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Wnt/β-Catenin Signaling pathway and potential targeting drugs This illustration details the interactions of targets with the potential targeting agents (ellipse with Rx followed by drug name) connected by solid line(s). Additional proteins and targets in this pathway (for which no current drug has been identified) are depicted. Types of interaction relationships are annotated in the figure. Additional drugs for targets are annotated in Supplementary Table 6 (Supplemental Digital Content 2, http://links.lww.com/JTO/A10). Data were analyzed through the use of Ingenuity Pathways Analysis (Ingenuity® Systems, www.ingenuity.com) and printed with permission. Journal of Thoracic Oncology 2009 4, 1313-1321DOI: (10.1097/JTO.0b013e3181ba20cf) Copyright © 2009 International Association for the Study of Lung Cancer Terms and Conditions